Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maxigen BiotechTPE:1783 -0.65%88 3-1 Month Momentum % is 1.00% as of Sep. 08, 2026. GuruFocus rates TPE:1783 with a GF Score™ of 88/100 and a GF Value™ of NT$58.34 (Significantly Undervalued). Among 839 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 59.36% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-08), Maxigen Biotech's 3-1 Month Momentum % is 1.00%.
The industry rank for Maxigen Biotech's 3-1 Month Momentum % or its related term are showing as below:
TPE:1783's 3-1 Month Momentum % is ranked better than 59.36% of 839
companies
in the Medical Devices & Instruments industry
Industry Median: -2
vs TPE:1783: 1.00
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Maxigen Biotech 3-1 Month Momentum % Related Terms
TPE:1783 vs ISRG, BDX, RMD: 3-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a 3-1 Month Momentum % of 1.00% as of Sep. 08, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Maxigen Biotech and its competitors. According to the industry distribution chart, Maxigen Biotech ranks #341 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 40.6%.
Is Maxigen Biotech's 3-1 Month Momentum % too high?
Maxigen Biotech's current 3-1 Month Momentum % is 1.00%. Based on the distribution chart, Maxigen Biotech ranks #341 out of 839 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Maxigen Biotech has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's 3-1 Month Momentum % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #341 out of 839 companies for 3-1 Month Momentum %. This puts Maxigen Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Maxigen Biotech and its competitors. Maxigen Biotech's current 3-1 Month Momentum % is 1.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$58.34, compared to a current price of NT$38.05 — trading 34.8% below its estimated fair value. The current 3-1 Month Momentum % is 1.00%. Maxigen Biotech's overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current 3-1 Month Momentum % is 1.00% as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$38.05 is trading 34.8% below its estimated GF Value™ of NT$58.34.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
3-1 Month Momentum %: 1.00%
GF Value™: NT$58.34 vs. price of NT$38.05 (34.8% below fair value)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
88GF Score
Get the complete analysis for TPE:1783
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
